{"id":"W3173725877","doi":"10.1159/000513486","title":"Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study","year":2021,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Bevacizumab; Medicine; Internal medicine; Hazard ratio; Sorafenib; Hepatocellular carcinoma; Gastroenterology; Progression-free survival; Population; Phases of clinical research; Oncology; Clinical endpoint; Randomized controlled trial; Clinical trial; Confidence interval; Cancer; Chemotherapy; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006860938,0.0004438286,0.001094776,0.0001497026,0.0002382212,0.0002034376,0.0003714308,0.0001241354,0.0006463949],"category_scores_gemma":[0.00009243822,0.0002714293,0.0001512669,0.001098369,0.0001091857,0.0003217554,0.0001760726,0.0003734709,0.00003755495],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004828597,"about_ca_system_score_gemma":0.0007334634,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0123365,"about_ca_topic_score_gemma":0.005808264,"domain_scores_codex":[0.996838,0.0007000918,0.0005031849,0.0007164968,0.000721398,0.0005208093],"domain_scores_gemma":[0.9983559,0.000302805,0.000166574,0.0007746695,0.0002411227,0.0001589222],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1838967,0.003451316,0.7974388,0.0001052855,0.0006155811,0.006540092,0.005354702,0.00001416501,0.000207348,0.0001069067,0.0001472088,0.002121892],"study_design_scores_gemma":[0.9267568,0.002145923,0.03388885,0.000136545,0.001947274,0.0001536729,0.001775904,0.03073858,0.001336831,0.00005362315,0.0005451157,0.0005208683],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9833558,0.008258672,0.00005148085,0.0006538001,0.0002613661,0.005240662,0.00003362652,0.0000435634,0.002101074],"genre_scores_gemma":[0.9959877,0.0003099088,0.0001776791,0.0002021245,0.0002180695,0.001686961,0.0002897823,0.00006218074,0.001065638],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7635499,"threshold_uncertainty_score":0.9999738,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1069567075284236,"score_gpt":0.3480448685584838,"score_spread":0.2410881610300601,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}